Delayed immunologic thrombocytopenia induced by abciximab

被引:14
作者
Nurden, P [1 ]
Clofent-Sanchez, G
Jais, C
Bermejo, E
Leroux, L
Coste, P
Nurden, AT
机构
[1] Hop Cardiol, Hematol Lab, FR21, IFR4, F-33604 Pessac, France
[2] Hop Cardiol, Serv Soins Intensifs, F-33604 Pessac, France
[3] Univ Victor Segalem Bordeaux, RMSB, UMR 5536, Bordeaux, France
关键词
Abciximab; percutaneous coronary intervention; delayed thrombocytopenia; thrombotic risk;
D O I
10.1160/TH04-04-0237
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Abciximab is an anti-GPIIb-IIIa drug widely used to prevent thrombotic complications during percutaneous coronary intervention. We now report on the immunologic origin of thrombocytopenia developing between 7 and 12 days after the onset of abciximab infusion. Antibodies directed against abciximab-coated platelets were located in 5 patients with delayed thrombocytopenia, just as they were present in a patient whose platelet count fell within a few hours after receiving the drug. Abciximab-dependent IgG antibody was revealed in serum using control platelets in the monoclonal antibody immobilization of platelet antigens assay (MAIPA) performed with SZ22, a MoAb to GPIIb. The presence of IgG antibodies specific for platelets sensitized with abciximab was confirmed by flow cytometry. They were not located in 13 patients receiving abciximab but whose platelet counts remained stable. For three patients, antibodies were transient and their presence related to the extent of the thrombocytopenia. Surprisingly, antibody-containing plasma from three patients induced abciximab-dependent activation and aggregation of normal platelets, a finding confirmed by electron microscopy. Immunogold labeling revealed that abciximab was associated with platelets in the aggregate, suggesting that its inhibitory effect was overcome by the platelet stimulation. In summary, these results show that abciximab-dependent thrombocytopenia can be delayed and potentially prothrombotic.
引用
收藏
页码:820 / 828
页数:9
相关论文
共 43 条
[31]   Multiple discontinuous ligand-mimetic antibody binding sites define a ligand binding pocket in integrin αIIbβ3 [J].
Puzon-McLaughlin, W ;
Kamata, T ;
Takada, Y .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (11) :7795-7802
[32]   Platelet glycoprotein IIb/IIIa inhibitors - Recognition of a two-edged sword? [J].
Quinn, MJ ;
Plow, EF ;
Topol, EJ .
CIRCULATION, 2002, 106 (03) :379-385
[33]   Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy [J].
Reddy, MS ;
Carmody, TJ ;
Kereiakes, DJ .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2001, 52 (04) :486-488
[34]   Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia [J].
Seiffert, D ;
Stern, AM ;
Ebling, W ;
Rossi, RJ ;
Barrett, YC ;
Wynn, R ;
Hollis, GF ;
He, BK ;
Kieras, CJ ;
Pedicord, DL ;
Cromley, DA ;
Hua, TA ;
Stein, RB ;
Daly, RN ;
Sferruzza, A ;
Pieniaszek, HJ ;
Billheimer, JT .
BLOOD, 2003, 101 (01) :58-63
[35]  
Sharma Sanjiv, 2002, Journal of Cardiovascular Pharmacology and Therapeutics, V7, P21, DOI 10.1177/107424840200700i103
[36]  
Simoons ML, 1997, LANCET, V349, P1429
[37]  
Suleiman Mahmoud, 2003, J Invasive Cardiol, V15, P319
[38]   Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention [J].
Tardiff, BE ;
Califf, RM ;
Tcheng, JE ;
Lincoff, AM ;
Sigmon, KN ;
Harrington, RA ;
Mahaffey, KW ;
Ohman, EM ;
Teirstein, PS ;
Blankenship, JC ;
Kitt, MM ;
Topol, EJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (01) :88-96
[39]   Abciximab readministration - Results of the ReoPro readministration registry [J].
Tcheng, JE ;
Kereiakes, DJ ;
Lincoff, AM ;
George, BS ;
Kleiman, NS ;
Sane, DC ;
Cines, DB ;
Jordan, RE ;
Mascelli, MA ;
Langrall, MA ;
Damaraju, L ;
Schantz, A ;
Effron, MB ;
Braden, GA .
CIRCULATION, 2001, 104 (08) :870-875
[40]  
Topol E, 1998, NEW ENGL J MED, V339, P436